TMZ-CD40L was a potent stimulator of human myeloid cells and T-cell responses. Further, CD40L-mediated stimulation increased tumor-infiltrating T cells in vivo, ...

The Fc engineering abrogates the platelet activation that is triggered by FcγRIIa stimulation by immune complexes. 17 Frexalimab targets CD40L, which is expressed on a variety of cells, including ...

Slowing down of tumor growth induced by coexpression of CD40L and CD70. On day 0, C57BL/6 mice were injected s.c. in one flank with 1 × 10 5 B16F10 cells. Four transfected pools of cells were ...

In the context of inflammation, antigen-presenting cells and endothelial cells express CD40L. 12 CD40L-CD40 interaction regulates oxidative stress, thrombosis, and vascular disease and has an ...

F(ab´) 2 Preparation. The F(ab´) 2 fragment of the CD40L-specific antibody (MR1) was prepared by pepsin digestion using the ImmunoPure F(ab´) 2 kit (Pierce) according to the manufacturer´s ...

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis November 02, 2020 08:00 AM Eastern Standard Time ...

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumours, reports it has partnered with Helmholtz Munich to acquire the ...

Disease activity in relapsing MS patients significantly fell following treatment with frexalimab, a novel second-generation investigational anti-CD40L antibody developed by Sanofi, according to a ...

Bristol Myers Squibb has exercised its option to globally license Obsidian Therapeutics' CD40L-armed cell therapy. The deal gives Bristol Myers control of a drug designed to counter the antigen ...

Three CD40L SNPs (rs3092920, rs3092952, rs3092936) were analyzed for association with transplant-associated thrombotic microangiopathy, overall nonrelapse mortality (NRM), and NRM after acute ...